Efficacy of nab ‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial
Oncol Lett. 2024 Feb 19;27(4):161. doi: 10.3892/ol.2024.14293. eCollection 2024 Apr.ABSTRACTPatients with advanced pancreatic cancer (PC) need a cost-effective treatment regimen. The present study was designed to compare the efficacy and safety of nab-paclitaxel plus S-1 (AS) and gemcitabine plus S-1 (GS) regimens in patients with chemotherapy-naïve advanced PC. In this open-label, multicenter, randomized study named AvGmPC, eligible patients with chemotherapy-naïve advanced PC were randomly assigned (1:1) to receive AS (125 mg/m2 nab-paclitaxel, days 1 and 8; 80-120 mg S-1, days 1-14) or GS (1,000 mg/m2 gemcitabine, days 1 and 8; 80-120 mg S-1, days 1-14). The treatment was administered every 3 weeks until intolerable toxicity or disease progression occurred. The primary endpoint was progression-free survival (PFS). Between December 2018 and March 2022, 101 of 106 randomized patients were treated and evaluated for analysis (AS, n=49; GS, n=52). As of the data cutoff, the median follow-up time was 11.37 months [95% confidence interval (CI), 9.31-13.24]. The median PFS was 7.16 months (95% CI, 5.19-12.32) for patients treated with AS and 6.41 months (95% CI, 3.72-8.84) for patients treated with GS (HR=0.78; 95% CI, 0.51-1.21; P=0.264). The AS regimen showed a slightly improved overall survival (OS; 13.27 vs. 10.64 months) and a significantly improved ORR (44.90 vs. 15.38%; P=0.001) compared with the GS regimen. In the subgroup analyses, PFS and OS benefits were observed in p...
Source: Oncology Letters - Category: Cancer & Oncology Authors: Xi Guo Wenhui Lou Yaolin Xu Rongyuan Zhuang Lie Yao Junwei Wu Deliang Fu Jun Zhang Jing Liu Yefei Rong Dayong Jin Wenchuan Wu Xuefeng Xu Yuan Ji Lili Wu Minzhi Lv Xiuzhong Yao Xiaowei Liu Dansong Wang Tiantao Kuang Liang Liu Wenquan Wang Tianshu Liu Yuhon Source Type: research
More News: Alopecia | Anemia | Cancer | Cancer & Oncology | Chemotherapy | Genetics | Pancreas | Pancreatic Cancer | Study | Thrombocytopenia | Toxicology